Cellectis S.A. (NASDAQ:CLLS – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $5.46.
CLLS has been the topic of several recent research reports. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research report on Tuesday, September 15th. Robert W. Baird decreased their price objective on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, September 15th. Wells Fargo & Company lowered their target price on Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 15th. Weiss Ratings raised Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Barclays cut Cellectis from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $9.00 to $1.30 in a research note on Wednesday, September 16th.
Check Out Our Latest Research Report on Cellectis
Institutional Trading of Cellectis
Cellectis Stock Down 0.7%
CLLS stock opened at $1.40 on Wednesday. The company has a fifty day moving average price of $2.56 and a 200 day moving average price of $3.09. Cellectis has a 12 month low of $1.25 and a 12 month high of $5.48. The company has a market cap of $140.48 million, a price-to-earnings ratio of -2.15 and a beta of 3.00. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37.
Cellectis (NASDAQ:CLLS – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.
About Cellectis
Cellectis is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic cell therapies for the treatment of cancer. The company uses its TALEN gene-editing technology to modify immune cells, including T cells, with the goal of creating “off-the-shelf” therapies that can be manufactured in advance and administered to multiple patients.
Cellectis’ development programs include UCART, or Universal Chimeric Antigen Receptor T-cell, therapies designed to target specific cancer antigens.
Recommended Stories
- Five stocks we like better than Cellectis
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
